Delivery Nanomaterials for Cancer Therapy
A special issue of Materials (ISSN 1996-1944). This special issue belongs to the section "Advanced Nanomaterials and Nanotechnology".
Deadline for manuscript submissions: closed (10 March 2023) | Viewed by 3389
Special Issue Editors
Interests: nanomaterial; gene therapy; gene expression; drug delivery; cell transfection
Special Issue Information
Dear Colleagues,
Nanomaterial use in biomedicine has grown extensively in recent decades. Particular focus has been devoted to nanoparticles as drug delivery systems in cancer treatment as nanosized drug carriers possess specific advantages when compared to conventional drugs. Namely, conjugation of conventional drugs with nanocarriers improves drug stability and biocompatibility. Furthermore, it promotes drug accumulation due to better enhanced permeability and retention effect. Importantly, it allows cancer cell targeting and helps to overcome drug resistance.
Although there is still a little bit of uncertainty in the use of nanocarriers in human cancer treatment, we believe in their success. This uncertainty is mostly based on the heterogenic, often unpredictable behavior of various nanomaterials. Since each nanomaterial possesses advantages and disadvantages, researchers tend to define the specific conditions of use for a particular nanomaterial (mainly the size, shape, preparation method, charge, and coating). A big step ahead has been the development of nanocarriers consisting of different nanoparticles, boosting the performance of the final drug carrier.
In this Special Issue, we plan to gather representative delivery approaches based on different nanomaterials, including hybrid structures with the final aim to target cancer cells. We expect contributions based on basic science as well as translational research in the fields of biological and biochemical experimentation as well as material research.
Dr. Veronika Benson
Dr. Parastoo Pourali
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Materials is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomaterial
- cancer therapy
- drug delivery
- cancer targeting
- nanocarriers
